glp-1 fda approved In a major milestone for obesity care, the has Wegovy® as the first oral receptor agonist for chronic weight management in adults with obesity or overweight and related conditions FDA approves Foundayo, an oral

Geen wachttijd, direct starten met jouw dokter begeleid afvalprogramma

With 64% Galactomyces Ferment Filtrate, rice ceramide, and a powerful blend of vitamin C derivatives, squalane, and ceramide complex, it deeply hydrates, strengthens the skin barrier, and enhances radiance

GLP-1 , ,

Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial

Delayed Gastric Emptying One of cagrilintide's most pronounced effects is slowing the rate of gastric emptying through activation of amylin receptors in the area postrema and vagal afferent pathways [5] : Central Nervous System Signaling: Activation of AMY1 receptors in the area postrema initiates vagal efferent signals that reduce gastric motility and pyloric relaxation [15] Direct Peripheral Effects: AMY3 receptor activation in the stomach and proximal small intestine may contribute to local motor function regulation [16] Metabolic Consequences: Delayed gastric emptying reduces the rate of glucose appearance in the bloodstream, lowering postprandial glucose excursions without increasing insulin demand [5] In Phase 2 trials, cagrilintide demonstrated dose-dependent reductions in gastric emptying rate, with effects sustained over the week-long dosing interval [9]